Nirsevimab Vaccine safety data Main navigation COVID-19 vaccines Influenza vaccines Mpox (monkeypox) vaccine National Immunisation Program schedule vaccines Nirsevimab RSV vaccines Vaccine safety in Australia AusVaxSafety summary reports AusVaxSafety has been conducting active safety surveillance of Beyfortus (nirsevimab) – a new long-acting injectable monoclonal antibody product used for the prevention of severe respiratory syncytial virus (RSV) disease in infants – at participating sites in New South Wales and Queensland throughout the 2024 winter season.In Australia, nirsevimab is currently only available to infants and young children through state-managed programs in New South Wales, Queensland and Western Australia.Safety data are gathered via surveys sent to recipients in the days following nirsevimab administration.The Western Australia RSV immunisation program also includes active safety surveillance, with reports published through Government of Western Australia Department of Health channels.Surveillance of nirsevimab is underway. This page will be updated once enough data to enable meaningful analysis is collected by AusVaxSafety. Vaccine safety data Main navigation COVID-19 vaccines Influenza vaccines Mpox (monkeypox) vaccine National Immunisation Program schedule vaccines Nirsevimab RSV vaccines Vaccine safety in Australia AusVaxSafety summary reports News & events All news & events 02 April 2026 | News AusVaxSafety begins surveillance of 2026 influenza vaccines, including new nasal spray option 05 March 2026 | News New LP.8.1 COVID-19 vaccines well tolerated, new AusVaxSafety data show 14 July 2025 | News Fewer adverse events reported following NIP pneumococcal vaccine change 03 June 2025 | News New AusVaxSafety data confirms Abrysvo RSV vaccine is well tolerated during pregnancy; adverse events comparable to other maternal vaccinations